Fentanyl buccal tablets recalled due to incorrect or missing package insert
Teva Pharmaceuticals USA Inc is recalling Fentanyl Buccal Tablets 800mcg due to incorrect or missing package inserts. The recall affects 3,032 units distributed nationwide.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: This is an FDA Class III recall due to a documentation issue (missing or incorrect package insert) with no reported illnesses, injuries, or deaths. Per the rubric, documentation issues are classified as Level 1 (Low).
Plain-English summary
Teva Pharmaceuticals USA Inc is recalling specific lots of Fentanyl Buccal Tablets CII, 800mcg. The product is packaged in cartons of 28 buccal tablets (4 tablets per card, 7 cards per carton). The affected lot numbers are 42617832 (expiration 06/2023), 42619530 (expiration 08/2023), and 100020532 (expiration 11/2024).
The recall is due to incorrect or missing package inserts. The package insert provides critical information necessary for the safe and proper use of the medication.
A total of 3,032 units were distributed nationwide under Rx-only status. The product was distributed by Mayne Pharma in Greenville, NC.
Patients and healthcare providers in possession of affected lots should consult with their pharmacist or healthcare provider regarding this recall.
The recalled product
- Product
- Fentanyl Buccal Tablets CII, 800mcg, packaged in cartons of 28 Buccal Tablets (4 tablets x 7 cards), Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834, NDC 51862-638-28
- Manufacturer
- Teva Pharmaceuticals USA Inc
- Category
- Drug — Opioid
- Hazard
- labeling-error
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot#: 42617832
- Exp 06/2023
- 42619530
- Exp 08/2023
- 100020532
- Exp 11/2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27